MCID: MLG068
MIFTS: 66

Malignant Glioma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Malignant Glioma

MalaCards integrated aliases for Malignant Glioma:

Name: Malignant Glioma 37 12 51 14 69
Glioma 41 69
Malignant Neuroglial Tumor 12
Glioma, Malignant 12
Glial Cell Tumor 12
Neuroglial Tumor 12

Classifications:



Summaries for Malignant Glioma

Disease Ontology : 12 A cell type cancer that has material basis in glial cells and is located in brain or located in spine.

MalaCards based summary : Malignant Glioma, also known as glioma, is related to meningioma, familial and glioma. An important gene associated with Malignant Glioma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Gliadel Wafer and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain or, brain and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Malignant Glioma

Diseases in the Glioma family:

Malignant Glioma

Diseases related to Malignant Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 meningioma, familial 32.5 EGF GFAP PTEN TERT TP53
2 glioma 32.1 CDK4 CDKN2A EGF EGFR MMP2 MMP9
3 astrocytoma 31.5 CDK4 CDKN2A EGF EGFR GFAP IL13RA2
4 arteriovenous malformation 30.6 MMP9 PTEN VEGFA
5 ependymoma 30.4 EGFR GFAP MGMT
6 brain cancer 30.2 EGF EGFR GFAP MGMT PTEN TP53
7 medulloblastoma 30.1 CASP3 CASP8 GFAP IL13RA2 MGMT TP53
8 pilocytic astrocytoma 29.8 CDK4 CDKN2A GFAP KDR MGMT PTEN
9 glioblastoma 29.7 CDK4 CDKN2A EGF EGFR MGMT PTEN
10 melanoma 29.2 CDK4 CDKN2A PTEN PTK2 TERT TP53
11 glioblastoma multiforme 28.6 CDK4 CDKN2A EGF EGFR GFAP IL13RA2
12 brain stem glioma 11.0
13 adult brain stem glioma 11.0
14 mixed glioma 11.0
15 mismatch repair cancer syndrome 11.0
16 malignant ependymoma 11.0
17 villous adenocarcinoma 10.8 EGFR MMP2 MMP9
18 frontal convexity meningioma 10.7 GFAP TP53
19 extracranial arteriovenous malformation 10.7 MMP2 MMP9
20 brain ependymoma 10.7 EGFR TP53
21 squamous cell carcinoma of the larynx 10.7 CDKN2A EGFR TP53
22 adenomyosis 10.7 MMP2 MMP9 VEGFA
23 brain stem astrocytic neoplasm 10.7 CDKN2A TP53
24 anaplastic oligodendroglioma 10.7 CDKN2A EGFR MGMT
25 nasal cavity squamous cell carcinoma 10.7 CDKN2A MMP2 MMP9
26 gliofibroma 10.7 GFAP TP53
27 odontogenic myxoma 10.7 MMP2 MMP9 VEGFA
28 oropharynx cancer 10.7 CDKN2A EGFR TP53
29 anal squamous cell carcinoma 10.7 CDKN2A MGMT TP53
30 focal myositis 10.7 MMP2 MMP9
31 basaloid squamous cell carcinoma 10.7 CDKN2A EGFR TP53
32 oligoastrocytoma 10.7 GFAP MGMT
33 vulva cancer 10.7 CDKN2A EGFR TP53
34 primary peritoneal carcinoma 10.7 EGFR TP53 VEGFA
35 fibrillary astrocytoma 10.7 GFAP MGMT TP53
36 bladder squamous cell carcinoma 10.7 CDKN2A PTEN TP53
37 pre-malignant neoplasm 10.7 CDKN2A EGFR TP53
38 pleomorphic xanthoastrocytoma 10.7 GFAP MGMT TP53
39 mucinous adenocarcinoma 10.7 CDKN2A EGFR TP53
40 internal hemorrhoid 10.7 CASP3 MMP2 MMP9
41 spinal cord astrocytoma 10.7 GFAP MGMT TP53
42 penile cancer 10.7 CDKN2A EGFR TP53
43 ring chromosome 7 10.7 CDK4 TP53
44 serous cystadenocarcinoma 10.7 MMP2 TP53 VEGFA
45 in situ carcinoma 10.7 CDKN2A EGFR TP53
46 necrotizing sialometaplasia 10.7 CDKN2A GFAP TP53
47 malignant ovarian surface epithelial-stromal neoplasm 10.7 MMP2 TP53 VEGFA
48 ovary epithelial cancer 10.7 MMP2 TP53 VEGFA
49 actinic keratosis 10.7 CDKN2A MMP2 TP53
50 dedifferentiated liposarcoma 10.7 CDK4 CDKN2A TP53

Graphical network of the top 20 diseases related to Malignant Glioma:



Diseases related to Malignant Glioma

Symptoms & Phenotypes for Malignant Glioma

GenomeRNAi Phenotypes related to Malignant Glioma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.92 PTK2 CASP3 TERT CASP8 TNFRSF10B CDKN2A
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.92 PTK2 CASP3 TERT CASP8 TNFRSF10B CDKN2A
3 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 PTEN CDK4 EGFR VEGFA PPME1
4 Decreased viability with paclitaxel GR00179-A-1 9.26 PTK2 CASP3 EGFR
5 Decreased viability with paclitaxel GR00179-A-3 9.26 EGFR

MGI Mouse Phenotypes related to Malignant Glioma:

43 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.5 EGFR CDKN2A GFAP MMP9 CASP3 CDK4
2 immune system MP:0005387 10.47 EGFR CDKN2A EGF GFAP MMP9 CASP3
3 cardiovascular system MP:0005385 10.45 GFAP EGFR CDKN2A KDR MMP9 CASP3
4 mortality/aging MP:0010768 10.45 EGFR CDKN2A GFAP MMP9 CASP3 CDK4
5 cellular MP:0005384 10.44 EGFR CDKN2A CASP8 KDR CASP3 GFAP
6 growth/size/body region MP:0005378 10.44 GFAP EGFR CDKN2A EGF CASP8 KDR
7 hematopoietic system MP:0005397 10.43 EGFR CDKN2A KDR MMP9 CASP3 CDK4
8 endocrine/exocrine gland MP:0005379 10.39 EGFR CDKN2A EGF CASP8 CASP3 MGMT
9 digestive/alimentary MP:0005381 10.37 GFAP EGFR CDKN2A EGF MMP9 CASP3
10 integument MP:0010771 10.3 EGFR CDKN2A EGF CASP8 KDR MMP9
11 muscle MP:0005369 10.29 EGFR CDKN2A GFAP MMP9 CASP3 CDK4
12 nervous system MP:0003631 10.28 EGFR CDKN2A CASP8 KDR MMP9 CASP3
13 neoplasm MP:0002006 10.27 EGFR CDKN2A MMP9 CDK4 MGMT MMP2
14 embryo MP:0005380 10.24 VEGFA CDKN2A EGFR CASP8 KDR CDK4
15 liver/biliary system MP:0005370 10.21 EGFR CDKN2A CASP8 KDR CDK4 PTEN
16 normal MP:0002873 10.14 EGF EGFR KDR GFAP CDK4 MMP2
17 respiratory system MP:0005388 10.03 EGFR CDKN2A MMP9 CASP3 MGMT MMP2
18 reproductive system MP:0005389 10 EGF CDKN2A EGFR CASP3 CDK4 PTK2
19 renal/urinary system MP:0005367 9.92 EGFR CASP8 CASP3 CDK4 PTEN MMP9
20 pigmentation MP:0001186 9.85 CDKN2A EGFR CASP3 CDK4 PTEN TP53
21 skeleton MP:0005390 9.7 CDKN2A EGFR MMP2 KDR CASP3 PTEN
22 vision/eye MP:0005391 9.4 GFAP EGFR CDKN2A EGF KDR MMP9

Drugs & Therapeutics for Malignant Glioma

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gliadel Wafer 17 45 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997

Drugs for Malignant Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 399)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 85622-93-1 5394
3
Dabrafenib Approved, Investigational Phase 4,Phase 2,Phase 1 44462760 44516822
4
Trametinib Approved Phase 4,Phase 2 871700-17-3 11707110
5
Lactitol Investigational Phase 4 585-86-4 3871
6 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 Protein Kinase Inhibitors Phase 4,Phase 1,Phase 2
9
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1 154-93-8 2578
10
Cisplatin Approved Phase 3,Phase 2 15663-27-1 2767 441203 84093
11
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
12
Ifosfamide Approved Phase 3 3778-73-2 3690
13
Levoleucovorin Approved, Investigational Phase 3,Phase 1 68538-85-2
14
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
15
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
16
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
17
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
18
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
19
Aminolevulinic acid Approved Phase 3,Phase 2,Phase 1 106-60-5 137
20
Carboplatin Approved Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 38904 498142
21
Bevacizumab Approved, Investigational Phase 2, Phase 3, Phase 1, Early Phase 1 216974-75-3
22
Procarbazine Approved, Investigational Phase 3,Phase 2 671-16-9 4915
23
Flucytosine Approved, Investigational Phase 2, Phase 3,Phase 1 2022-85-7 3366
24
Fluorouracil Approved Phase 2, Phase 3,Phase 1 51-21-8 3385
25
Octreotide Approved, Investigational Phase 2, Phase 3 83150-76-9 6400441 383414
26
Somatostatin Approved, Investigational Phase 2, Phase 3 38916-34-6, 51110-01-1 53481605
27
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5282379 5538
28
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
29 Thiotepa Approved, Investigational Phase 3,Phase 2 52-24-4 5453
30
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1 149647-78-9 5311
31
Dalteparin Approved Phase 3 9005-49-6
32
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
33
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
34
Armodafinil Approved, Investigational Phase 3,Phase 2 112111-43-0
35
Modafinil Approved, Investigational Phase 3,Phase 2 68693-11-8 4236
36
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
37
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
38
Benzocaine Approved, Investigational Phase 3,Phase 2 1994-09-7, 94-09-7 2337
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
42
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
43 tannic acid Approved, Nutraceutical Phase 3,Phase 2
44
Vitamin C Approved, Nutraceutical Phase 3,Phase 1,Phase 2 50-81-7 54670067 5785
45
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
46 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
47 Antimetabolites Phase 3,Phase 2,Phase 1
48 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
49 Antimitotic Agents Phase 3,Phase 2,Phase 1
50 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 632)

# Name Status NCT ID Phase Drugs
1 Dabrafenib and/or Trametinib Rollover Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
2 Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
3 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
4 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
5 Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas Completed NCT01167322 Phase 3 NPC-07 for oral administration
6 Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
7 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
8 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
9 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
10 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
11 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
12 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
13 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
14 Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients Completed NCT00135876 Phase 3 dalteparin
15 Chloroquine for Treatment of Glioblastoma Multiforme Completed NCT00224978 Phase 3 Chloroquine
16 The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
17 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Recruiting NCT02892708 Phase 3
18 A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas Recruiting NCT02629757 Phase 3 β-elemene
19 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3 Temozolomide;α-IFN
20 Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma Recruiting NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
21 3D Ultra Sound for Resection of Brain Tumors Recruiting NCT02150564 Phase 3
22 Fluorescence-guided Surgery for Low- and High-grade Gliomas Recruiting NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
23 The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma Recruiting NCT02414165 Phase 2, Phase 3 Toca FC;Lomustine;Temozolomide
24 iMRI Guided Resection in Cerebral Glioma Surgery Recruiting NCT01479686 Phase 3
25 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
26 Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients Recruiting NCT02796261 Phase 3 Eflornithine;Lomustine;Lomustine
27 International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013) Not yet recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
28 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
29 XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema Withdrawn NCT00226668 Phase 3 hCRF;placebo hCRF
30 Avastin / Irinotecan in Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT01144988 Phase 2 Bevacizumab / Irinotecan
31 Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas Unknown status NCT01670890 Phase 2 TMZ;TMZ plus CDDP
32 A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Unknown status NCT00683761 Phase 1, Phase 2 131I-TM601
33 Radiation With Concomitant and Then Sequential Temozolomide in Malignant Glioma Unknown status NCT00283543 Phase 2 Gliadel Wafer;Temozolomide
34 Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma Unknown status NCT01235845 Phase 1, Phase 2
35 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
36 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2 carboplatin;tamoxifen citrate;temozolomide
37 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
38 A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660283 Phase 2 Temozolomide
39 A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma Unknown status NCT00660621 Phase 2 Temozolomide and Bevacizumab
40 Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma Unknown status NCT02481960 Phase 1, Phase 2
41 Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma Unknown status NCT00360945 Phase 2 cisplatin;temozolomide
42 Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma Unknown status NCT02698280 Phase 2 Bevacizumab;Nimustine
43 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2 131-I-TM-601;131I-TM601
44 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
45 Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00906516 Phase 2 Neuradiab in combination with Bevacizumab (Avastin)
46 Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer Unknown status NCT02139579 Phase 2 Bevacizumab
47 Carbon Ion Radiotherapy for Recurrent Gliomas Unknown status NCT01166308 Phase 1, Phase 2
48 CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients Completed NCT02575261 Phase 1, Phase 2
49 A Phase II Study to Treat Advanced Malignant Glioma Completed NCT00427440 Phase 2 AMG 102 at 20 mg/kg;AMG 102 at 10 mg/kg
50 Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas Completed NCT00766753 Phase 1, Phase 2

Search NIH Clinical Center for Malignant Glioma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Malignant Glioma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Malignant Glioma:
ALD-451, bone marrow-derived cells for malignant glioma
Embryonic/Adult Cultured Cells Related to Malignant Glioma:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905

Cochrane evidence based reviews: glioma

Genetic Tests for Malignant Glioma

Anatomical Context for Malignant Glioma

The Foundational Model of Anatomy Ontology organs/tissues related to Malignant Glioma:

18
Brain Or

MalaCards organs/tissues related to Malignant Glioma:

38
Brain, T Cells, Bone, Endothelial, Bone Marrow, Testes, Lung

Publications for Malignant Glioma

Articles related to Malignant Glioma:

(show top 50) (show all 1211)
# Title Authors Year
1
Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. ( 29432077 )
2018
2
ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. ( 29017962 )
2018
3
Antitumor effect of a new nano-vector with miRNA-135a on malignant glioma. ( 29343959 )
2018
4
B<i>m</i>K CT enhances the sensitivity of temozolomide-induced apoptosis of malignant glioma U251 cells<i>in vitro</i>through blocking the AKT signaling pathway. ( 29434848 )
2018
5
Efficacy of ribavirin against malignant glioma cell lines: Follow-up study. ( 29251333 )
2018
6
Development of temozolomide coated nano zinc oxide for reversing the resistance of malignant glioma stem cells. ( 29208287 )
2018
7
Lrig1 is a haploinsufficient tumor suppressor gene in malignant glioma. ( 29391393 )
2018
8
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma. ( 29133513 )
2018
9
Immunotherapies for malignant glioma. ( 29242608 )
2018
10
Intraoperative Photodynamic Diagnosis Using Talaporfin Sodium Simultaneously Applied for Photodynamic Therapy against Malignant Glioma: A Prospective Clinical Study. ( 29441040 )
2018
11
Long Non-Coding RNA HOXA-AS2 Regulates Malignant Glioma Behaviors and Vasculogenic Mimicry Formation via the MiR-373/EGFR Axis. ( 29310118 )
2018
12
"Simple Methods to Derive Primary Malignant Glioma Cell Lines and Assay of Cellular Damage for Preclinical Studies". ( 29405781 )
2018
13
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. ( 29404979 )
2018
14
CCR7 Mediates TGF-I^1-Induced Human Malignant Glioma Invasion, Migration, and Epithelial-Mesenchymal Transition by Activating MMP2/9 Through the Nuclear Factor KappaB Signaling Pathway. ( 28817313 )
2017
15
A novel indication of thioredoxin-interacting protein as a tumor suppressor gene in malignant glioma. ( 28781647 )
2017
16
Relationship between radiation dose and microbleed formation in patients with malignant glioma. ( 28797254 )
2017
17
Human fibulin-3 protein variant expresses anti-cancer effects in the malignant glioma extracellular compartment in intracranial xenograft models. ( 29290950 )
2017
18
Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy. ( 28938558 )
2017
19
Prognostic awareness and communication preferences among caregivers of patients with malignant glioma. ( 29125714 )
2017
20
Gene Expression and Methylation Analyses Suggest DCTD as a Prognostic Factor in Malignant Glioma. ( 28912488 )
2017
21
Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. ( 28650441 )
2017
22
Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells. ( 28555424 )
2017
23
Impact of a novel biomarker, T-LAK cell-originating protein kinase (TOPK) expression on outcome in malignant glioma. ( 29271010 )
2017
24
Hypoxia-induced production of peptidylarginine deiminases and citrullinated proteins in malignant glioma cells. ( 27818200 )
2017
25
NSPc1 promotes cancer stem cell self-renewal by repressing the synthesis of all-trans retinoic acid via targeting RDH16 in malignant glioma. ( 28394339 )
2017
26
Tracking Functional Tumor Cell Subpopulations of Malignant Glioma by Phasor Fluorescence Lifetime Imaging Microscopy of NADH. ( 29211022 )
2017
27
CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma. ( 28534507 )
2017
28
Prognostic Awareness, Prognostic Communication, and Cognitive Function in Patients with Malignant Glioma. ( 28645200 )
2017
29
Apparent transverse relaxation (R2a89) on MRI as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma. ( 29193849 )
2017
30
Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination. ( 29383115 )
2017
31
Long non-coding RNA HOTTIP promotes hypoxia-induced epithelial-mesenchymal transition of malignant glioma by regulating the miR-101/ZEB1 axis. ( 28886531 )
2017
32
Wavelength-specific lighted suction instrument for 5-aminolevulinic acid fluorescence-guided resection of deep-seated malignant glioma: technical note. ( 28665248 )
2017
33
IKBKE regulates cell proliferation and epithelial-mesenchymal transition of human malignant glioma via the Hippo pathway. ( 28548934 )
2017
34
The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8(+)T Cell Anti-tumor Activity. ( 28480325 )
2017
35
The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma-Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. ( 28488122 )
2017
36
The regulator of calcineurin 1 (RCAN1) inhibits nuclear factor kappaB signaling pathway and suppresses human malignant glioma cells growth. ( 28061453 )
2017
37
Malignant glioma-primitive neuroectodermal tumor recurring as PNET-like only subdural collection: Case report. ( 29119041 )
2017
38
Screening critical genes associated with malignant glioma using bioinformatics analysis. ( 28901452 )
2017
39
Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway. ( 28401302 )
2017
40
DNA methylation-mediated caspase-8 downregulation is associated with anti-apoptotic activity and human malignant glioma grade. ( 28204824 )
2017
41
Study of antioxidant effects on malignant glioma cells by constructing a tumor-microvascular structure on microchip. ( 28595721 )
2017
42
Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma. ( 28594449 )
2017
43
Evaluation of rat C6 malignant glioma using spectral computed tomography. ( 28810555 )
2017
44
5-Aminolevulinic acid fluorescence guided resection of malignant glioma: Hong Kong experience. ( 28844780 )
2017
45
Cytotoxicity induced by carbon nanotubes in experimental malignant glioma. ( 28860763 )
2017
46
MiR-129 triggers autophagic flux by regulating a novel Notch-1/ E2F7/Beclin-1 axis to impair the viability of human malignant glioma cells. ( 26824182 )
2016
47
Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy. ( 27920506 )
2016
48
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. ( 27826680 )
2016
49
Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment. ( 27192459 )
2016
50
Akt and I^-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. ( 27423571 )
2016

Variations for Malignant Glioma

Copy number variations for Malignant Glioma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 74684 13 110300000 115169878 Deletion Malignant glioma
2 75161 13 16300000 19500000 Deletion Malignant glioma
3 75381 13 19500000 32200000 Deletion Malignant glioma
4 77097 13 40100000 45200000 Deletion Malignant glioma
5 178248 3 69788586 70017488 Amplification MITF Malignant glioma

Expression for Malignant Glioma

Search GEO for disease gene expression data for Malignant Glioma.

Pathways for Malignant Glioma

Pathways related to Malignant Glioma according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.27 CASP3 CASP8 CDK4 EGF EGFR GFAP
2
Show member pathways
13.94 CASP3 CASP8 CDKN2A EGF EGFR KDR
3
Show member pathways
13.82 CASP3 CASP8 CDK4 CDKN2A EGF EGFR
4
Show member pathways
13.81 CDK4 CDKN2A EGF EGFR KDR MMP2
5
Show member pathways
13.75 CASP3 CASP8 EGF EGFR IL13RA2 KDR
6
Show member pathways
13.58 CDK4 EGF EGFR KDR MMP2 MMP9
7
Show member pathways
13.51 CASP3 EGF EGFR IL13RA2 KDR PTEN
8
Show member pathways
13.46 CASP3 EGF EGFR IL13RA2 MMP2 MMP9
9
Show member pathways
13.43 CASP3 EGF EGFR KDR MMP2 MMP9
10
Show member pathways
13.39 CASP3 CASP8 EGF EGFR IL13RA2 KDR
11
Show member pathways
13.14 EGF EGFR KDR PTEN PTK2 TP53
12
Show member pathways
13.08 CASP3 CASP8 KDR PTK2 TP53 VEGFA
13
Show member pathways
13.03 CASP3 CDK4 CDKN2A EGF EGFR KDR
14
Show member pathways
12.99 EGF EGFR KDR PTEN PTK2 VEGFA
15
Show member pathways
12.98 CASP3 CASP8 MMP9 TNFRSF10B TNFSF10 TP53
16
Show member pathways
12.91 CASP3 CASP8 CDKN2A TNFRSF10B TNFSF10 TP53
17
Show member pathways
12.89 CASP3 CASP8 CDK4 TNFRSF10B TNFSF10 TP53
18
Show member pathways
12.89 CDK4 CDKN2A EGF EGFR PTEN TERT
19 12.88 CASP3 CASP8 EGF EGFR KDR TP53
20
Show member pathways
12.82 CASP3 CASP8 CDK4 EGF EGFR KDR
21
Show member pathways
12.74 KDR MMP2 MMP9 PTK2 VEGFA
22
Show member pathways
12.73 CASP3 CASP8 KDR TNFRSF10B TNFSF10 VEGFA
23
Show member pathways
12.69 KDR MMP2 MMP9 PTK2 VEGFA
24
Show member pathways
12.69 CASP3 CASP8 CDK4 MMP9 PTEN TP53
25 12.62 CASP3 CDKN2A EGFR MMP9 PTEN TP53
26
Show member pathways
12.62 CDK4 CDKN2A EGFR MMP2 MMP9 PTK2
27
Show member pathways
12.61 CASP3 CASP8 EGF EGFR PTK2 TP53
28
Show member pathways
12.58 EGF EGFR PTK2 TP53 VEGFA
29
Show member pathways
12.57 CASP3 CASP8 EGFR KDR PTK2 TP53
30
Show member pathways
12.5 CASP3 EGF EGFR KDR VEGFA
31
Show member pathways
12.48 EGF EGFR KDR PTK2 VEGFA
32
Show member pathways
12.44 EGF EGFR GFAP IL13RA2
33
Show member pathways
12.44 CASP3 CASP8 CDK4 CDKN2A PTEN TNFRSF10B
34
Show member pathways
12.44 CASP3 CASP8 EGFR KDR MMP2 PTEN
35 12.41 CASP3 CASP8 CDK4 CDKN2A TP53
36
Show member pathways
12.37 CASP3 CASP8 TNFRSF10B TNFSF10
37
Show member pathways
12.35 EGFR KDR PTEN PTK2 VEGFA
38 12.33 CASP3 CASP8 TNFRSF10B TNFSF10
39
Show member pathways
12.33 CASP3 CDK4 EGFR KDR PTEN PTK2
40
Show member pathways
12.29 CASP3 CASP8 CDK4 PTEN TNFRSF10B TNFSF10
41 12.27 EGF EGFR PTEN PTK2
42 12.26 CDK4 CDKN2A PTEN TP53
43
Show member pathways
12.25 CDK4 CDKN2A EGF EGFR TP53 VEGFA
44 12.23 CASP3 EGFR KDR MMP2 MMP9 PTK2
45 12.22 CASP3 EGF EGFR MMP2 MMP9 TP53
46
Show member pathways
12.21 EGF EGFR MMP2 PTEN
47 12.21 EGF EGFR KDR PTK2
48 12.2 EGFR MMP2 PTEN TNFRSF10B TP53
49 12.2 CDK4 CDKN2A MGMT PTEN TP53
50 12.19 KDR MMP2 MMP9 PTK2 TP53 VEGFA

GO Terms for Malignant Glioma

Cellular components related to Malignant Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.26 CASP3 CASP8 EGFR KDR
2 death-inducing signaling complex GO:0031264 8.62 CASP3 CASP8

Biological processes related to Malignant Glioma according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 CDK4 EGFR PTK2 TNFRSF10B
2 extracellular matrix organization GO:0030198 9.97 GFAP KDR MMP9 PTK2
3 positive regulation of cell proliferation GO:0008284 9.95 CDK4 EGF EGFR KDR PTEN PTK2
4 peptidyl-tyrosine phosphorylation GO:0018108 9.94 EGF EGFR KDR PTK2
5 response to ethanol GO:0045471 9.88 CASP8 MGMT PTEN TP53
6 positive regulation of protein phosphorylation GO:0001934 9.88 EGFR KDR MMP9 PTK2 VEGFA
7 cellular response to hypoxia GO:0071456 9.87 PTEN TERT TP53 VEGFA
8 cellular response to mechanical stimulus GO:0071260 9.86 CASP8 EGFR TNFRSF10B
9 response to estradiol GO:0032355 9.86 CASP3 CASP8 EGFR PTEN
10 cellular response to organic cyclic compound GO:0071407 9.85 CASP3 CASP8 MGMT
11 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.85 KDR PTK2 VEGFA
12 regulation of protein stability GO:0031647 9.85 CDKN2A PTEN TERT
13 positive regulation of MAP kinase activity GO:0043406 9.84 EGF EGFR VEGFA
14 vasculogenesis GO:0001570 9.83 KDR PTK2 VEGFA
15 epidermal growth factor receptor signaling pathway GO:0007173 9.83 EGF EGFR PTK2
16 learning or memory GO:0007611 9.82 CASP3 EGFR PTEN
17 peptidyl-tyrosine autophosphorylation GO:0038083 9.81 EGFR KDR PTK2
18 angiogenesis GO:0001525 9.8 EGF KDR MMP2 PTEN PTK2 VEGFA
19 execution phase of apoptosis GO:0097194 9.79 CASP3 CASP8 PTK2
20 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.78 CASP8 TNFRSF10B TNFSF10
21 cellular response to reactive oxygen species GO:0034614 9.77 EGFR MMP9 TP53
22 response to antibiotic GO:0046677 9.77 CASP3 CASP8 TP53
23 response to organic cyclic compound GO:0014070 9.77 CASP3 EGFR MGMT PTEN TP53
24 positive regulation of release of cytochrome c from mitochondria GO:0090200 9.75 MMP9 TNFSF10 TP53
25 positive regulation of cell migration GO:0030335 9.73 EGF EGFR KDR MMP9 PTK2 VEGFA
26 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.72 MMP2 MMP9 TERT
27 macrophage differentiation GO:0030225 9.7 CASP8 MMP9 VEGFA
28 positive regulation of apoptotic process GO:0043065 9.7 CASP3 CDK4 CDKN2A MMP9 PTEN TNFSF10
29 positive regulation of positive chemotaxis GO:0050927 9.69 KDR VEGFA
30 positive regulation of catenin import into nucleus GO:0035413 9.69 EGF EGFR
31 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.69 CASP8 TNFRSF10B TNFSF10
32 negative regulation of organ growth GO:0046621 9.68 PTEN PTK2
33 positive regulation of protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:2000060 9.67 EGF PTEN PTK2
34 response to cobalt ion GO:0032025 9.64 CASP3 CASP8
35 central nervous system neuron axonogenesis GO:0021955 9.63 PTEN PTK2
36 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.63 CASP8 TNFRSF10B TNFSF10
37 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.62 KDR VEGFA
38 replicative senescence GO:0090399 9.61 CDKN2A TERT TP53
39 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.35 CASP3 CASP8 CDKN2A TNFRSF10B TNFSF10
40 negative regulation of apoptotic process GO:0043066 9.32 CASP3